Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
user
  1. Dashboard
  2. My Profile
  3. My Address
  4. My Orders
  5. Acro Membership
Login Register
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP Cytokines Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
There is no goods in the shopping cart !
My Cart|Secure Checkout
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ALK-1

ALK-1

Brief Information

Name:Activin receptor-like kinase 1
Target Synonym:EC:2.7.11.30,ACVRLK1,Activin A Receptor Type II-Like 1,Activin A Receptor, Type II-Like Kinase 1,EC 2.7.11,ALK-1,Serine/threonine-protein kinase receptor R3,TGF-B superfamily receptor type I,Activin receptor-like kinase 1,SKR3,ALK1,ACVRL1,Activin A Receptor Like Type 1,Activin A Receptor Type IL,TSR-I,EC 2.7.11.30,HHT2,ORW2,HHT
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
AL1-H5228 Human Human ALK-1 / ACVRL1 Protein, His Tag (MALS verified)
AL1-H5228-structure
AL1-H5228-sds
ACRO Quality

Part of Bioactivity data

AL1-H5228-SPR
ALK-1 MALS images

The purity of Human ALK-1, His Tag (Cat. No. AL1-H5228) is more than 90% and the molecular weight of this protein is around 18-28 kDa verified by SEC-MALS.

Synonym Name

ACVRL1,ACVRLK1,ALK-1,HHT,HHT2,ORW2,SKR3,TSR-I

Background

Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Ascrinvacumab PF-3446962; GT-90001; PF-3-446-962; GT-90001C; ALK-1; GT90001C; PF-03446962 Phase 2 Clinical Pfizer Inc Liver Neoplasms; Solid tumours; Neoplasms; Mesothelioma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Macular Degeneration Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap